Salute e Benessere

GenSci Launches Global Innovation Hub in Shanghai

Since its founding in 1997, GenSci has introduced several groundbreaking therapies, including the GenSci Recombinant Human Growth Hormone, GenSci Heng Recombinant Human Follicle-Stimulating Hormone and Jinfuning Recombinant Human Granulocyte-Stimulating Factor Gel. Since its founding in 1997, GenSci has introduced several groundbreaking therapies, including the GenSci Recombinant Human Growth Hormone, GenSci Heng Recombinant Human Follicle-Stimulating Hormone and Jinfuning Recombinant Human...
PR Newswire
24/12/2023

U.S. Food and Drug Administration issues Complete Response Letter for…

Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility The CRL is related to deficiencies identified at a third-party manufacturing facility following an inspection but are not specific to dasiglucagon. The CRL did not state any concerns about the clinical data package or safety of dasiglucagon...
Nasdaq GlobeNewswire
23/12/2023

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4 thfloor, 75013 Paris, France.At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommendations of the board of directors...
Nasdaq GlobeNewswire
22/12/2023

Groupe Casino : communiqué relatif aux achats d'actions

Communiqué relatif aux achats d'actions effectués dans les conditionsde l'article 5 du Règlement européen n° 596/2014 Le 21 décembre 2023, la société Casino, Guichard-Perrachon a racheté 28 000 actions au prix moyen de 0,66 € dans le cadre de la couverture des plans d'actions gratuites attribuées préalablement aux procédures collectives en cours.Les opérations sont détaillées dans l'annexe jointe au présent communiqué.Saint-Etienne, le 22 décembre 2023AnnexeI. ...
Nasdaq GlobeNewswire
22/12/2023

BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology…

About BioVaxys Technology Corp. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( www.biovaxys.com ), a biopharmaceuticals company based inVancouver, Canada, is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late-stage ovarian cancer and other tumor types. The Company is capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes...
PR Newswire
22/12/2023

Nexstim Plc: Correction to Company Announcement: Nexstim Plc's Financial…

Company Announcement, Helsinki, 22 December 2023 at 3 PM (EET) Nexstim Plc: Correction to Company Announcement: Nexstim Plc's Financial Information in 2024 and Updated Disclosure Policy Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") corrects the company announcement released by the Company on 21 December 2023 at 4 PM (EET) regarding the Company's financial information in 2024 and updated disclosure policy. In all language versions of the release, the date of the Annual…
Nasdaq GlobeNewswire
22/12/2023

iSTAR Medical continues European expansion with first MINIject® surgeries in the…

For immediate release iSTAR Medical continues European expansion with first MINIject ®surgeries in the NetherlandsWAVRE, Belgium — 22 December 2023 :iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces the successful first implantations of MINIject ®, the Company's bio-integrating, minimally-invasive glaucoma surgery (MIGS) device, in the Netherlands.Glaucoma is the cause of visual impairment or blindness in four percent...
Nasdaq GlobeNewswire
22/12/2023

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 22 December 2023– On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under…
Nasdaq GlobeNewswire
22/12/2023

Feminine Hygiene Market size to worth $63.5 billion by 2030, globally at a CAGR…

Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/3633 Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/3633 Secondly, innovative product launches by key players in the market have contributed to the growth of the feminine hygiene market. Companies are introducing advanced products with features like odor control, enhanced comfort, and better absorption to cater to the evolving customer...
PR Newswire
22/12/2023

NordVPN partners with Movember and doubles donations

Movember, renowned for its iconic moustache-growing campaign, focuses on addressing key issues affecting men, including mental health, suicide prevention, prostate cancer, and testicular cancer. NordVPN's commitment to supporting Movember reflects the company's dedication not only to online security but also to the well-being of individuals in the digital age. Movember, renowned for its iconic moustache-growing campaign, focuses on addressing key issues affecting men, including mental health,...
PR Newswire
22/12/2023

Nexstim receives Nexstim NBS System 5 order from Europe for Neurosurgery and…

Press release, Helsinki, 22 December 2023 at 9 AM (EET) Nexstim receives Nexstim NBS System 5 order from Europe for Neurosurgery and Neuroscience Use Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5. The system will mainly be used for neurosurgery and possible neuroscience use in the future.Nexstim's NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for presurgical mapping of the speech and motor cortices of…
Nasdaq GlobeNewswire
22/12/2023

Mendus announces clinical pipeline update

Press Release Stockholm, Sweden, December 22, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announced an update on the status and outlook of its clinical pipeline programs.Mendus reports completion of the long-term follow up of the MERECA trial studying the intratumoral immune primerilixadencelin metastatic renal cell carcinoma (mRCC). The long-term follow up data confirmed the observations previously...
Nasdaq GlobeNewswire
22/12/2023

Crossject signs ZEPIZURE® commercialization agreement for northern Europe

Crossject to receive up to €1 million on marketing approvals, plus a markup on sales linked to gross marginAgreement, with undisclosed strategic partner, allows Crossject to benefit from strong expertise in the field and provides impetus to commercial launches Dijon, France 22 December, 2023, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations,announces it has concluded a commercialization...
Nasdaq GlobeNewswire
22/12/2023

BioVaxys and Procare Health Agree to Termination of USA Distribution Agreement…

BioVaxys President and Chief Operating Officer Kenneth Kovan stated, "While we believe the Papilocare® is a highly promising product, the timetable of the regulatory pathway in the US is not aligned anymore with our strategic objectives to focus on immunotherapeutics. The termination of the agreement strengthens the balance sheet of BioVaxys and allows the management team to advance certain initiatives related to immunotherapy. We appreciate the continued partnership with Procare on the EU…
PR Newswire
22/12/2023

Ono Enters into Research Collaboration with UK Dementia Research Institute

As for such molecules identified through the collaboration, Ono will generate drug candidates against those target molecules and work towards the development and commercialization of new drugs for the treatment of dementia. As for such molecules identified through the collaboration, Ono will generate drug candidates against those target molecules and work towards the development and commercialization of new drugs for the treatment of dementia. Ono dedicates our drug discovery efforts...
PR Newswire
22/12/2023

Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for…

Ensitrelvir is an antiviral drug for COVID-19 that has already been approved under the emergency regulatory approval system in Japan. The drug is a 3CL protease inhibitor created through joint research between Hokkaido University and Shionogi. Ensitrelvir suppresses the replication of SARS-CoV-2 by selectively inhibiting 3CL protease. It is the first antiviral drug to show both clinical symptomatic efficacy for five typical Omicron-related symptoms and antiviral efficacy in patients with a mild…
PR Newswire
22/12/2023

Congenital Adrenal Hyperplasia Treatment Drug Market to Exhibit Immense Growth…

Key Takeaways from the Congenital Adrenal Hyperplasia Market Report Key Takeaways from the Congenital Adrenal Hyperplasia Market Report Discover which therapies are expected to grab the major congenital adrenal hyperplasia market share @Congenital Adrenal Hyperplasia Market Report Congenital Adrenal Hyperplasia Overview Congenital adrenal hyperplasia (CAH) constitutes a rare cluster of autosomal recessive disorders stemming from an inherited deficiency in enzymes crucial for...
PR Newswire
21/12/2023

Evaxion Biotech Announces Closing of Private Placement

MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company's management and board of directors with significant participation in the total offering COPENHAGEN, Denmark, Dec.21, 2023(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Nasdaq GlobeNewswire
21/12/2023

Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome

Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth SyndromeEqual Partnership with AFT Pharmaceuticals for Development of a Novel Locally-Acting Product Candidate in Burning Mouth Syndrome (HY-090)Strengthening Strategic Partnership with AFT Pharmaceuticals Following the Success of the Maxigesic® IV CollaborationLiège, Belgium – 21 December 2023, 06:30PM CET – Regulated information – Inside information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a...
Nasdaq GlobeNewswire
21/12/2023

IBA – Transparency Notification

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, December 21, 2023 18:00 Summary of the notificationIBA (Ion Beam Applications), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification...
Nasdaq GlobeNewswire
21/12/2023

CARBIOS publishes its second sustainability report and confirms its ambitions to…

PRESS RELEASE CARBIOS publishes its second sustainability report and confirms its ambitions to accelerate the circular economy for plasticClermont-Ferrand (France), 21 December 2023 (18:00 CET).CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, publishes its second Sustainability Report with 2022 as the reference year. Like the first, this report is not subject to...
Nasdaq GlobeNewswire
21/12/2023

IBA – Transparency Notification

IBA – TRANSPARENCY NOTIFICATION(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, December 21, 2023 18:00 Summary of the notificationIBA (Ion Beam Applications), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major...
Nasdaq GlobeNewswire
21/12/2023

Mithra and Rafa Laboratories sign binding Head of Terms to commercialize…

Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA ®in Israel Rafa Laboratories to receive the exclusive commercial rights for DONESTA® in Israel on the signing of the final license and supply agreementMithra is eligible to receive a total of EUR 2.05 million sales-related milestones, along with tiered double-digit royalties on annual net sales and payments at signature of the license agreement and for regulatory milestonesDONESTA®...
Nasdaq GlobeNewswire
21/12/2023

Navamedic ASA: Renewed contract signed with Vitaflo International Limited

"We are thrilled to have renewed the contract with Vitaflo International, which underpins the strength of Navamedic's marketing and distribution channels in the Nordics. The medical nutrition product portfolio represents one of Navamedic's key product offerings to our customers in the Nordics, and we look forward to continuing our collaboration and partnership with Vitaflo International," commented Kathrine Gamborg Andreassen, CEO of Navamedic. "We are thrilled to have renewed the…
PR Newswire
21/12/2023
Altri  Comunicati